The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton’s tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-cell lymphoma 2 inhibitor venetoclax. We provide a co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Eyre, Toby A., Roeker, Lindsey E., Fox, Christopher P., Gohill, Satyen H., Walewska, Renata, Walter, Harriet S., Forconi, Francesco, Broom, Angus, Arumainathan, Arvind, Brander, Danielle M., Allan, John N., Schuster, Stephen J., Hill, Brian T., Lansigan, Frederick, Cheson, Bruce D., Lamanna, Nicole, Coombs, Catherine C., Barr, Paul M., Skarbnik, Alan P., Shadman, Mazyar, Ujjani, Chaitra S., Pearson, Laurie, Pagel, John M., Jacobs, Ryan, Mato, Anthony R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7528953/
https://ncbi.nlm.nih.gov/pubmed/31682002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16271
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados